convEyXO

What we do: convEyXO is a pioneering Belgian biotech company dedicated to transforming the landscape of exosome-based therapies. We develop innovative solutions for fibrotic and chronic inflammatory diseases, as well as degenerative and aging-related conditions, with the goal of improving patients’ quality of life. Our proprietary technology platform harnesses small extracellular vesicles (exosomes) derived from immortalized cell lines, which we enhance by loading them with target-specific miRNAs to amplify their anti-inflammatory and regenerative properties. Our therapeutic portfolio is built through strategic partnerships in the health and biotech sectors, and we are active in both pharmaceutical biotechnology and hospital healthcare industries. Our mission is to address unmet medical needs by slowing cellular aging and developing advanced therapeutics that go beyond palliative care.

Where we are located: convEyXO is headquartered at BioPark Charleroi, Belgium, with additional presence at Gaston Geenslaan 1, 3001 Leuven, Belgium. Our location in one of Belgium’s leading biotech hubs provides access to a vibrant ecosystem of research, innovation, and collaboration.

Short history: Founded in 2019 by industry veterans with extensive experience in pharmaceutical development, convEyXO has rapidly established itself as a leader in exosome therapeutics. The company was built on decades of expertise in biologics and manufacturing, with a founding team that includes former senior executives from major pharmaceutical companies. Since its inception, convEyXO has developed a robust therapeutic pipeline and formed a joint venture, XomeXBio, with SomesTech to advance nanoengineering technologies for large-scale exosome loading, initially targeting musculoskeletal diseases and oncology.

Organization & culture: convEyXO is a medium-sized company with a team of about 15 passionate professionals, including experts in pharmaceutical development, biologics, and manufacturing. Our culture is rooted in integrity, collaboration, and innovation, with a strong emphasis on ethical responsibility and scientific excellence. We believe that every team member plays a vital role in our quest to build a better future in biotechnology. Our flat structure encourages the exchange of ideas and teamwork, enabling us to achieve ambitious goals together.

Recent developments: convEyXO continues to expand its therapeutic portfolio through strategic partnerships and is actively involved in pre-clinical development of its exosome-based therapies. The company’s joint venture, XomeXBio, represents a significant step in scaling up the production and loading of exosomes for targeted drug delivery, with a focus on high-prevalence unmet medical needs.